almediah.fr
» » Design & Experimental Evaluation of Allergen-Derived Peptides for Specific Immunotherapy of Allergic Diseases (Acta Biomedical Lovaniensia, 227)

Download Design & Experimental Evaluation of Allergen-Derived Peptides for Specific Immunotherapy of Allergic Diseases (Acta Biomedical Lovaniensia, 227) eBook

by Bo Wu

Download Design & Experimental Evaluation of Allergen-Derived Peptides for Specific Immunotherapy of Allergic Diseases (Acta Biomedical Lovaniensia, 227) eBook
ISBN:
9058671011
Author:
Bo Wu
Category:
Medicine & Health Sciences
Language:
English
Publisher:
Leuven Univ Pr (April 1, 2001)
Pages:
145 pages
EPUB book:
1664 kb
FB2 book:
1333 kb
DJVU:
1366 kb
Other formats
lrf txt lit rtf
Rating:
4.8
Votes:
184


PDF Opinion statement Allergic diseases are among the most common health . treatment of allergic disease by means of immunotherapy. of the allergic response is caused by the activation. of allergen-specific T cells, which produce pro-in-

PDF Opinion statement Allergic diseases are among the most common health issues worldwide. Panels of unmodified. recombinant allergens have already been shown to effectively replace natural al-. lergen extracts in therapy. of allergen-specific T cells, which produce pro-in-. flammatory cytokines and can lead to late-phase re-. actions and the more chronic forms of allergic. Although this phase of the allergic.

PDF Allergen specific immunotherapy (ASIT) and environmental control are currently considered the only etiologic treatments of allergic diseases such as allergic rhinoconjunctivitis, asthma and, in some cases, atopic.

PDF Allergen specific immunotherapy (ASIT) and environmental control are currently considered the only etiologic treatments of allergic diseases such as allergic rhinoconjunctivitis, asthma and, in some cases, atopic dermatitis. Allergen specific immunotherapy (ASIT) and environmental control are currently considered the only etiologic treatments of allergic diseases such as allergic rhinoconjunctivitis, asthma and, in some cases, atopic dermatitis. It has been firmly established that ASIT can alter the natural course of the disease.

Current treatments for allergic and autoimmune disease treat disease . and 2 derived peptides 75 Increase in IL-10-secreting regulatory cells; reduction in allergy symptoms to cedar pollen.

Current treatments for allergic and autoimmune disease treat disease symptoms or depend on. non-specific immune suppression. of allergen-specific T cells secreting distinct cytokines plays a crucial role in the onset and. cessation of allergic diseases. First, it is important to realise that allergic and non-allergic.

Allergen Immunotherapy for allergic rhinitis and asthma article updated by. .

Allergen Immunotherapy for allergic rhinitis and asthma article updated by Profs.

Allergen-specific immunotherapy (SIT) is an antigen-specific and disease-modifying form of.

Allergen-specific immunotherapy (SIT) is an antigen-specific and disease-modifying form of treatment. It is based on the therapeutic administration of the disease-causing allergens to allergic patients. These peptides are fused by recombinant technology onto a viral carrier protein to obtain a combination vaccine which induces protective immunity against allergy and viral infections.

Allergen-specific immunotherapy (AIT) was described as a therapeutic option for the treatment of allergies > 100 years ago. It is based on administration of allergen extracts and leads to the development of clinical allergen tolerance in selected patients.

Allergen-specific immunotherapy (AIT) was described as a therapeutic option for the treatment of allergies 100 years ago. According to current knowledge, AIT results in the restoration of immune tolerance toward the allergen of interest

The treatment has proven effective, but it requires repetitive administrations of allergen extracts over 3-5 years and is often associated with adverse events.

The treatment has proven effective, but it requires repetitive administrations of allergen extracts over 3-5 years and is often associated with adverse events. This implies the need for novel therapeutic strategies with reduced side effects and decreased treatment time, which would improve patients' compliance. Development of vaccines that are molecularly well defined and have improved safet. ONTINUE READING.

Allergen-specific preventive strategies based on recombinant . Allergen-specific immunotherapy with synthetic peptides. The concept of using PreS-bound allergen-derived peptides for the development of AIT vaccines seems to be broadly applicable for all allergen sources.

Allergen-specific preventive strategies based on recombinant allergen-based vaccine approaches and induction of T-cell tolerance are on the horizon and hold promise that allergy can be prevented. However, progress is limited by lack of resources needed for clinical studies, which are necessary for the development of these innovative strategies.

The treatment has proven effective, but it requires repetitive administrations of allergen extracts over 3–5 years and is often associated with adverse events. Allergen-derived peptides are designed to contain antigenic determinants of major allergens (epitopes) that are capable of activating the appropriate cellular and humoral responses while avoiding possible allergenic and/or reactogenic responses induced by whole allergens and allergen extracts.

Immunotherapy through repeated administration of allergens and augmentation of doses (hyposensibilization) with the purpose of decreasing the severity of type I allergic reactions or even its complete elimination is known already for a longer period of time

Immunotherapy through repeated administration of allergens and augmentation of doses (hyposensibilization) with the purpose of decreasing the severity of type I allergic reactions or even its complete elimination is known already for a longer period of time. This type of therapy is especially beneficial in allergies to Hymenoptera venom, allergic rhinoconjunctivitis, allergic asthma and is implemented in patients with previously proven allergy to appropriate allergens (insects, pollen, house dust mite, pet dander and other).